Have a personal or library account? Click to login
Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis Cover

Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis

Endocrine Regulations
Volume 55 (2021): Issue 3 (July 2021)
By: Diana Borges Duarte,  Ana Martins da Silva,  Claudia Freitas and  Helena Cardoso  
Open Access
|Sep 2021

Authors

Diana Borges Duarte

diana.sbduarte@gmail.com

Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar e Universitario do Porto, Oporto, Portugal

Ana Martins da Silva

Department of Neurology, Centro Hospitalar e Universitario do Porto, Oporto, Portugal

Claudia Freitas

Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar e Universitario do Porto, Oporto, Portugal

Helena Cardoso

Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar e Universitario do Porto, Oporto, Portugal
DOI: https://doi.org/10.2478/enr-2021-0018 | Journal eISSN: 1336-0329 | Journal ISSN: 1210-0668
Journal RSS Feed
Language: English
Page range: 169 - 173
Published on: Sep 13, 2021
Published by: Slovak Academy of Sciences, Mathematical Institute
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
ocrelizumab,
Graves´ disease,
immune reconstitution therapy,
multiple sclerosis
Related subjects:
Life sciences,
Molecular biology,
Neurobiology,
Medicine,
Basic medical science,
Basic medical science, other,
Clinical medicine,
Internal medicine,
Endocrinology, diabetology

© 2021 Diana Borges Duarte, Ana Martins da Silva, Claudia Freitas, Helena Cardoso, published by Slovak Academy of Sciences, Mathematical Institute
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 55 (2021): Issue 3 (July 2021)Next article